Dry Eye Syndromes
273
15
21
191
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Published Results
76 trials with published results (28%)
Research Maturity
191 completed trials (70% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.1%
14 terminated out of 273 trials
93.2%
+6.6% vs benchmark
32%
86 trials in Phase 3/4
40%
76 of 191 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 191 completed trials
Clinical Trials (273)
Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Efficacy and Safety Safety of Nutritears® in Adults With Dry Eye Syndrome
The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
Tolerability Comparison of Flarex to Lotemax SM
Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction
Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD
Therapeutic Effect of Stem Cell Eye Drops on Dry Eye Disease
Assessing the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs
Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
Blink Reminders and Meibomian Gland Loss in Digital Screen Users
Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED
Mechanisms of Light-based Therapies for Dry Eye Disease
Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution
Photobiomodulation With REd vs BluE Light (REBEL)
Protecting the Eyes of Gamers With Lubricating Eyedrops
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Prospective Study to Validate the Imaging Biomarker for NCP (R33)